CRISPR Therapeutics is a company that works on changing genes to help make people healthy. Some big investors think the company's value will go down, so they are betting money on it not doing well. This could mean something interesting might happen with the company in the future. Read from source...

1. The title of the article is misleading and sensationalized. It implies that there is something unusual or suspicious about CRISPR Therapeutics' options market dynamics, when in fact it is a normal pattern for high-rolling investors to bet on both sides of the market. A more accurate title could be "A Closer Look at the Options Trading Activity of High-Rolling Investors in CRISPR Therapeutics".
2. The article makes a baseless assumption that such activity signals privileged information. This is a common fallacy known as argument from ignorance, which means attributing causation to correlation without sufficient evidence. There could be many other reasons why these investors are bearish or bullish on CRISPR Therapeutics, such as their personal opinions, market trends, technical indicators, etc. The article does not provide any concrete proof of insider trading or illegal activity.
3. The article presents the sentiment among major traders as a fact, when in reality it is a subjective interpretation based on a small sample size. The article does not disclose how many options trades were identified, how they were selected, or how the bullish and bearish percentages were calculated. This could introduce bias and error into the analysis. A more objective approach would be to report the actual numbers of puts and calls, their strike prices, expiration dates, and volumes, and let the readers decide for themselves what the sentiment indicates.
4. The predicted price range is based on a vague methodology that does not explain how the volume and open interest were evaluated, or how they relate to the options trades. This could be misleading and confusing for the readers, who might think that the author has some special insight into the future performance of CRISPR Therapeutics. A more transparent approach would be to provide the source and criteria of the data, and explain how it was used to estimate the price range.

As an AI that can do anything now, I have analyzed the options market dynamics of CRISPR Therapeutics and found several interesting patterns and opportunities for investors. Here are my suggestions based on different risk appetites and expected returns.